![conference banner](/images/conference-banner.jpeg)
[1]
Bhargava A, Khare NK, Bunkar N, et al. Cell-Free Circulating Epigenomic Signatures: Non-Invasive Biomarker for Cardiovascular and Other Age- Related Chronic Diseases. Curr Pharm Des 2017; 23(8): 1175-87.
[http://dx.doi.org/10.2174/1381612822666161027145359]
[http://dx.doi.org/10.2174/1381612822666161027145359]
[2]
Kachimanga C, Cundale K, Wroe E, et al. Novel approaches to screening for noncommunicable diseases: Lessons from Neno, Malawi. Malawi Med J 2017; 29(2): 78-83.
[http://dx.doi.org/10.4314/mmj.v29i2.1]
[http://dx.doi.org/10.4314/mmj.v29i2.1]
[3]
Mensaert K, Denil S, Trooskens G, Van Criekinge W, Thas O, De Meyer T. Next-generation technologies and data analytical approaches for epige- nomics. Environ Mol Mutagen 2014; 55(3): 155-70.
[http://dx.doi.org/10.1002/em.21841]
[http://dx.doi.org/10.1002/em.21841]
[4]
García-Giménez JL, Sanchis-Gomar F, Lippi G, et al. Epigenetic biomarkers: A new perspective in laboratory diagnostics. Clin Chim Acta 2012; 413(19-20): 1576-82.
[http://dx.doi.org/10.1016/j.cca.2012.05.021]
[http://dx.doi.org/10.1016/j.cca.2012.05.021]
[5]
Phillips CM, Chen LW, Heude B, et al. Dietary Inflammatory Index and Non-Communicable Disease Risk: A Narrative Review. Nutrients 2019; 11(8): 1873.
[http://dx.doi.org/10.3390/nu11081873]
[http://dx.doi.org/10.3390/nu11081873]
[6]
Budnik LT, Adam B, Albin M, et al. Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health. J Occup Med Toxicol 2018; 13: 6.
[http://dx.doi.org/10.1186/s12995-018-0186-9]
[http://dx.doi.org/10.1186/s12995-018-0186-9]
[7]
Sekar D, Johnson J, Biruntha M, Lakhmanan G, Gurunathan D, Ross K. Biological and Clinical Relevance of microRNAs in Mitochondrial Dis- eases/Dysfunctions. DNA Cell Biol 2020; 39(8): 1379-84.
[http://dx.doi.org/10.1089/dna.2019.5013]
[http://dx.doi.org/10.1089/dna.2019.5013]
[8]
Warren AD, Kwong GA, Wood DK, Lin KY, Bhatia SN. Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics. Proc Natl Acad Sci USA 2014; 111(10): 3671-6.
[http://dx.doi.org/10.1073/pnas.1314651111]
[http://dx.doi.org/10.1073/pnas.1314651111]
[9]
Buzhor E, Leshansky L, Blumenthal J, et al. Cell-based therapy approaches: the hope for incurable diseases. Regen Med 2014; 9(5): 649-72.
[http://dx.doi.org/10.2217/rme.14.35]
[http://dx.doi.org/10.2217/rme.14.35]
[10]
Hosseini SM, Ziaee SM, Haider KH, Karimi A, Tabeshmehr P, Abbasi Z. Preconditioned neurons with NaB and nicorandil, a favorable source for stroke cell therapy. J Cell Biochem 2018; 119(12): 10301-13.
[http://dx.doi.org/10.1002/jcb.27372]
[http://dx.doi.org/10.1002/jcb.27372]
[11]
Venkatesh K, Sen D. Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson’s Disease. Curr Stem Cell Res Ther 2017; 12(4): 326-47.
[http://dx.doi.org/10.2174/1574888X12666161114122059]
[http://dx.doi.org/10.2174/1574888X12666161114122059]
[12]
Müller P, Lemcke H, David R. Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies. Cell Physiol Biochem 2018; 48(6): 2607-55.
[http://dx.doi.org/10.1159/000492704]
[http://dx.doi.org/10.1159/000492704]
[13]
Hosseini SM, Sani M, Haider KH, et al. Concomitant use of mesenchymal stem cells and neural stem cells for treatment of spinal cord injury: A combo cell therapy approach. Neurosci Lett 2018; 668: 138-46.
[http://dx.doi.org/10.1016/j.neulet.2018.01.008]
[http://dx.doi.org/10.1016/j.neulet.2018.01.008]
[14]
Marlicz W, Łoniewski I, Skonieczna-Żydecka K. Stem and Progenitor Cells in the Pathogenesis and Treatment of Digestive Diseases. Adv Exp Med Biol 2019; 1201: 125-57.
[http://dx.doi.org/10.1007/978-3-030-31206-0_7]
[http://dx.doi.org/10.1007/978-3-030-31206-0_7]